Diligence memo · auto-generated · as of July 2, 2026
Jaguar Health, Inc.
Jaguar Health, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Jaguar Health, Inc. operates in Pharmaceuticals, based in San Francisco.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Jaguar Health, Inc. has raised $151M in disclosed capital across 35 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $45M on 2017-07-31.
Most recent recorded round closed around 2025-11-12.
Valuation (modeled)modeled
Provath models Jaguar Health, Inc. at approximately $59M (range $35M–$74M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.39× the median modeled value of Series C Pharmaceuticals companies in 2025–2027 (26 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 4 months.
Last raise 8 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 10.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 95% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 46% of those peers.
Closest niche peers: BlossomHill Therapeutics, Inc., Rivus Pharmaceuticals, Inc., Sparrow Pharmaceuticals, Inc., Arthrosi Therapeutics, Inc., Altesa BioSciences, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.